Thymosin Alpha-1 Life Events That Affect Dosing

HealthRX.com

No label dose change for surgery, infection or stress

Print or save as PDF

  • Label schedule / Zadaxin (Italy): 1.6 mg twice weekly, weeks 1 to 4 and 8 to 12 [1]
  • US status / not FDA-approved; no US-approved dose [1]
  • Pregnancy and breastfeeding / contraindicated on the Italian label [1]
  • Allergy, autoimmune disease, other immune drugs / label advises caution [1]
  • Half-life / about 1.8 to 2.6 hours; no accumulation after five daily doses [1]
  • US compounding status / category 3 on FDA's list for outsourcing facilities; in none of the three categories on FDA's list for pharmacies and physicians [2][3]

The only dose the label sets

Thymosin alpha-1 (thymalfasin) is a 28-amino-acid peptide, the synthetic version of one isolated from thymosin fraction 5, a thymus extract. It is described as an immune modulator that augments T-cell function [1][4]. It is not FDA-approved. It has four US orphan drug designations, but orphan designation is a separate process and not an approval, so there is no US label and no US-approved dose [1].

The finished-product instruction is Italy's Zadaxin label: 1.6 mg of powder subcutaneously or intramuscularly twice weekly for 4 weeks starting at the first influenza vaccination, repeated from week 8 to week 12 at the second vaccination, in immunocompromised people [1]. That is a fixed calendar built around two vaccination dates, not a dose titrated to lab values.

Pregnancy, breastfeeding and other immune drugs

The Italian label contraindicates Zadaxin in pregnancy and breastfeeding and says it is not for children. It advises caution in people with allergies or autoimmune disease and in people taking other immune-modulating drugs [1].

Surgery, infection, stress, travel and chemotherapy

No dose change for these situations is described in the label details or trials available. Trials tested thymosin alpha-1 as a treatment for specific diseases rather than as a dose adjusted for a life event.

In a trial of 361 patients with severe sepsis in six Chinese hospitals, 28-day mortality was 26.0% with thymosin alpha-1 versus 35.0% in the control group (P=0.062 unstratified, log rank P=0.049; relative risk 0.74, 95% CI 0.54 to 1.02) [5]. A 2026 Cochrane review of 10 trials in 1,349 adults with chronic hepatitis B rated the evidence very low certainty for possible lower mortality, and the reviewers said they were not sure thymosin alpha-1 helps [6].

What people on Reddit report

Accounts from people who kept taking thymosin alpha-1 during illness or recovery and described how it affected them and how they adjusted their dosing.

welshpudding · Immunology

But it does seem like a good time to do it given the immune response. I'm wondering whether to stick through the uptick in symptoms or hold off.

Reports feeling more unwell after each recent dose during a recovery from infection, and is weighing whether to keep going or pause.

Read the source discussion

welshpudding · Immunology

I basically get more ill for a few days every time I take the TA1. So it's a bit of a hinderance to general work and life stuff. I might try lower doses to see if that is easier to handle.

Says they feel worse for a few days after each dose, which affects daily life, and is considering a lower dose.

Read the source discussion

The_Bodybuilder1 · PeptideDiscussion

I'll take a bolus dose for a few days if I do get sick. There really isn't a blood test that I am aware of to run to see if it's working but good metrics to track are getting sick less and recovering from illnesses quicker when you do get sick.

Says they take a short higher-dose course when they fall ill and track how often they get sick and how fast they recover.

Read the source discussion

Questions worth asking

Choose the questions you want to keep

Safety and US compounding status

FDA searched its adverse-event database in April 2024 and found zero reports for thymosin alpha-1 [1]. FDA's Pharmacy Compounding Advisory Committee voted 4 yes and 17 no in December 2024 on adding it to the pharmacy bulks list [8]. Thymosin alpha-1 now sits in FDA's nominated-but-withdrawn table, after previously being in category 2, and FDA's concerns about immunogenicity for certain routes of administration remain posted [9].

Check what you know

Think you have it? Try 4 quick questions and see what the article says.

1. According to the Italian Zadaxin label, when does the 4-week dosing period start?

Question 1 of 4

Score: 0 right, 0 of 4 answered

Can thymosin alpha-1 be used in pregnancy or while breastfeeding?
The Italian Zadaxin label contraindicates it in both [1]. Thymosin alpha-1 is not FDA-approved in the United States, so there is no US label [1].
What does the label say about other immune-modulating drugs?
The Italian label advises caution when thymosin alpha-1 is given with other immune-modulating drugs, and in people with allergies or autoimmune disease [1].
Is thymosin alpha-1 FDA-approved?
No. FDA found no US application for it, and its orphan drug designations are a separate process from approval. FDA lists national authorizations in Italy, India and Hong Kong [1].
How long does thymosin alpha-1 stay in the body?
After subcutaneous injection in healthy volunteers it peaks at about 0.7 to 2 hours and clears with a half-life of about 1.8 to 2.6 hours, with no accumulation after five daily doses [1].

Reader questions

What people actually ask

Short answers drawn from the sources this article cites.

How much thymosin alpha 1 should I take daily?

There is no US-approved daily dose. The Italian Zadaxin label sets 1.6 mg twice weekly, not daily, for 4 weeks from the first influenza vaccination and again from week 8 to week 12. The schedule is tied to vaccination dates rather than to lab values.

How long does it take thymosin alpha 1 to work?

No time to effect is established for thymosin alpha-1. The available data are pharmacokinetic: after subcutaneous injection in healthy volunteers it peaks at about 0.7 to 2 hours and has a half-life of about 1.8 to 2.6 hours, with no accumulation after five daily doses.

What happens if you have too much thymosin?

No overdose effects are described. FDA searched its adverse-event database in April 2024 and found zero reports for thymosin alpha-1. Whether higher amounts cause harm is not established, and the label's cautions cover allergies, autoimmune disease and other immune-modulating drugs.

Show all 11 referencesHide references
  1. U.S. Food and Drug Administration.
  2. U.S. Food and Drug Administration.
  3. U.S. Food and Drug Administration.
  4. Ancell CD, Phipps J, Young L. Thymosin alpha-1. Am J Health Syst Pharm. 2001;58(10):879-85; quiz 886-8.
  5. Wu J, Zhou L, Liu J, Ma G, Kou Q, He Z, et al. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. Crit Care. 2013;17(1):R8.
  6. Naing C, Ni H, Aung HH, Aye SN, Nikolova D, Poovorawan Y, et al. Thymosin-ɑ1 for people with chronic hepatitis B. Cochrane Database Syst Rev. 2026;9(9):CD014610.
  7. Lim SG, Wai CT, Lee YM, Dan YY, Sutedja DS, Wee A, et al. A randomized, placebo-controlled trial of thymosin-alpha1 and lymphoblastoid interferon for HBeAg-positive chronic hepatitis B. Antivir Ther. 2006;11(2):245-53.
  8. U.S. Food and Drug Administration.
  9. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
  10. Reddit participants. Thymosin alpha 1 daily vs twice weekly administration (r/Immunology). Accessed 2026-11-11.
  11. Reddit participants. Thymosin Alpha-1 (r/PeptideDiscussion). Accessed 2026-11-11.
Evidence overview for lifestyle thymosin alpha 1: Thymosin Alpha-1 Life Events That Affect Dosing